Haemonetics Corporation
HAE
$87.58
$0.971.12%
NYSE
| 03/28/2026 | 12/27/2025 | 09/27/2025 | 06/28/2025 | 03/29/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.33B | 1.32B | 1.33B | 1.35B | 1.36B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.33B | 1.32B | 1.33B | 1.35B | 1.36B |
| Cost of Revenue | 544.53M | 527.88M | 543.22M | 564.81M | 589.36M |
| Gross Profit | 789.49M | 790.40M | 784.63M | 781.23M | 771.47M |
| SG&A Expenses | 431.25M | 421.59M | 421.41M | 426.35M | 427.77M |
| Depreciation & Amortization | 44.00M | 44.80M | 46.10M | 47.18M | 48.26M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.08B | 1.06B | 1.07B | 1.10B | 1.13B |
| Operating Income | 255.45M | 262.92M | 254.49M | 245.45M | 234.30M |
| Income Before Tax | 128.03M | 227.17M | 217.11M | 210.53M | 212.07M |
| Income Tax Expenses | 30.72M | 51.73M | 48.92M | 47.19M | 44.39M |
| Earnings from Continuing Operations | 97.31 | 175.44 | 168.19 | 163.34 | 167.68 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 97.31M | 175.44M | 168.19M | 163.34M | 167.68M |
| EBIT | 255.45M | 262.92M | 254.49M | 245.45M | 234.30M |
| EBITDA | 361.07M | 368.82M | 362.04M | 353.96M | 343.18M |
| EPS Basic | 2.04 | 3.65 | 3.44 | 3.30 | 3.34 |
| Normalized Basic EPS | 2.93 | 3.12 | 2.94 | 2.78 | 2.79 |
| EPS Diluted | 2.02 | 3.64 | 3.43 | 3.28 | 3.32 |
| Normalized Diluted EPS | 2.93 | 3.11 | 2.92 | 2.76 | 2.77 |
| Average Basic Shares Outstanding | 188.72M | 191.69M | 195.18M | 198.49M | 201.32M |
| Average Diluted Shares Outstanding | 189.23M | 192.48M | 196.13M | 199.71M | 202.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |